CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Explore patent oppositions filed by Alnylam Pharmaceuticals against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Last updated on: Aug 7, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

Compositions And Methods For Increasing The Serum Half-Life Of A Therapeutic Agent Targeting Complement C5ALEXION PHARMACEUTICALSAug 27, 2020
Further Novel Forms Of Interfering Rna MoleculesSILENCE THERAPEUTICSOct 31, 2018
Further Novel Forms Of Interfering Rna MoleculesATUGENAug 17, 2018
Futher Novel Forms Of Interfering Rna MoleculesSILENCE THERAPEUTICSOct 19, 2017

Explore Alnylam Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 7, 2025
Patent NumberGrant DateTitleTotal Oppositions
Apr 27, 2022Modified Rnai Agents1
Apr 20, 2022Angiopoietin-Like 3 (Angptl3) Irna Compositions And Methods Of Use Thereof1
Jun 23, 2021Ketohexokinase (Khk) Irna Compositions And Methods Of Use Thereof1
Jun 20, 2018Angiopoietin-Like 3 (Angptl3) Irna Compostions And Methods Of Use Thereof1

Top competitors of Alnylam Pharmaceuticals

List of top competitors of Alnylam Pharmaceuticals based on patent oppositions.